雷奈佐利; 吗啉恶酮; (S)-N-[[3-(3-氟-4-吗啉基苯基)-2-氧代-5-噁唑烷基]甲基]乙酰胺; 利奈唑胺中间体; 利奈唑酮; (S)-N-{[3-(3-氟-4-(4-吗啉基)苯)2-氧-5-唑啉]甲基}-乙酰胺; (S)-N-3-(3-氟-4-吗啉基苯基)-2-氧代-5-噁唑烷基甲基乙酰胺; 利奈唑胺; 利萘唑胺; 吗啉噁酮
Linezolid; NDA 21-130 Zyvox; N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; Linezlid; Zyvoxid; Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-; Zyvox; (S)-N-((3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; N-{[(5S)-3-(3-Fluor-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamid; N-({(5S)-3-[3-Fluor-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamid; Zyvoxam; Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; Zyvoxa; MFCD00937825; N-({(5S)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-{[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide; N-{[(5S)-3-(3-fluoro-4-morpholin-4-ylphényl)-2-oxo-1,3-oxazolidin-5-yl]méthyl}acétamide; N-({(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; (s)-n-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; N-({(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-({(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; (S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
Store at RT
水溶性:不溶;水溶解度:610 mg/l 25 °C;微溶:二氯甲烷;不溶:乙醇
1、 摩尔折射率:82.96 2、 摩尔体积(cm3/mol):259.0 3、 等张比容(90.2K):680.7 4、 表面张力(dyne/cm):47.7 5、 极化率(10-24cm3):32.89
1.疏水参数计算参考值(XlogP):0.7 2.氢键供体数量:1 3.氢键受体数量:6 4.可旋转化学键数量:4 5.互变异构体数量:2 6.拓扑分子极性表面积71.1 7.重原子数量:24 8.表面电荷:0 9.复杂度:472 10.同位素原子数量:0 11.确定原子立构中心数量:1 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1
1.性状:白色结晶 2.熔点(ºC):181.5~182.5